Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of 14C-VX-993 in healthy subjects
NCT06886269Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VX-993 in pain, sponsored by Vertex Pharmaceuticals. Primary endpoints: Terminal Phase Rate Constant (λz) of VX-993 in Plasma, Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of VX-993 in Plasma and 16 more. Started Mar 2025; status: completed.
02
Drugs
VX-993
03
Conditions
pain
Beyond the preview
Go deeper on NCT06886269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06886269.